The purpose of this observational study is to assess the effectiveness and safety of Nivolumab plus Ipilimumab with or without chemotherapy as first-line treatment for participants with untreated advanced or recurrent NSCLC in the real world setting in Japan.
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Duration of treatment
Timeframe: Up to 1 year
Rates of participants with second-line treatment
Timeframe: Up to 1 year
Overall survival (OS)
Timeframe: Up to 1 year
Incidence of Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 Grade 3 or higher immune-related adverse events [irAEs]
Timeframe: Up to 1 year
Time to next treatment [(TNT)
Timeframe: Up to 1 year
Treatment-free survival (TFS)
Timeframe: Up to 1 year
Treatment continuation rate
Timeframe: Up to 1 year
Incidence of treatment-related adverse events (TRAEs) leading to treatment discontinuation
Timeframe: Up to 1 year